Roots Analysis has announced the addition of the “Herceptin® (Trastuzumab) Biosimilars ” report to its list of offerings.

The first trastuzumab biosimilar was approved in Europe in 2017 and within a year, the EMA approved four more (2018). Considering the opportunity associated with this blockbuster product, its corresponding biosimilar developer landscape is also vast.

To order this report, which features 50+ insightful figures, depicting key analytical takeaways, please visit this link